Stay updated with breaking news from Ptom Keith Roach. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
INNOVATIVE ACCESS DEAL SECURED IN THE UK FOR LYNPARZA (OLAPARIB) TO TREAT BRCA-MUTATED CANCERS Olaparib is the first and only treatment available within NHS England for patients with germline BRCA mutations in early breast cancer (stage I-IIIA) and patients with metastatic castration-resistant prostate cancer (...
STRICTLY EMBARGOED UNTIL Tuesday 6 September 2022 00:01 BST LYNPARZA (olaparib) APPROVED IN GREAT BRITAIN AS ADJUVANT TREATMENT FOR PATIENTS WITH GERMLINE BRCA-MUTATED HER2-NEGATIVE HIGH-RISK EARLY BREAST CANCER First and only approved medicine in Great Britain which targets germline BRCA mutations in pati...
Approval is significant as waning restrictions present significant threats to many immunocompromised people across the UK - News - PharmaTimes
NICE EXPANDS GUIDANCE FOR LOKELMA®▼(sodium zirconium cyclosilicate) IN ADULT PATIENTS WITH PERSISTENT HYPERKALAEMIA People living with persistent hyperkalaemia in England, Wales and Northern Ireland will now be able to access repeat prescriptions of sodium zirconium cyclosilicate (SZC) in the community.[1]T...
NICE EXPANDS GUIDANCE FOR LOKELMA®▼(sodium zirconium cyclosilicate) IN ADULT PATIENTS WITH PERSISTENT HYPERKALAEMIA People living with persistent hyperkalaemia in England, Wales and Northern Ireland will now be able to access repeat prescriptions of sodium zirconium cyclosilicate (SZC) in the community.[1]T...